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A B S T R A C T
Background
Motor neuron disease (MND), which is also known as amyotrophic lateral sclerosis (ALS), causes a wide range of symptoms but the
evidence base for the effectiveness of the symptomatic treatment therapies is limited.
Objectives
To summarise the evidence from Cochrane Systematic Reviews of all symptomatic treatments for MND.
Methods
We searched the Cochrane Database of Systematic Reviews (CDSR) on 15 November 2016 for systematic reviews of symptomatic
treatments for MND. We assessed the methodological quality of the included reviews using the Assessment of Multiple Systematic
Reviews (AMSTAR) tool and the GRADE approach. We followed standard Cochrane study (review) selection and data extraction
procedures. We reported findings narratively and in tables.
Main results
We included nine Cochrane Systematic Reviews of interventions to treat symptoms in people with MND. Three were empty reviews
with no included randomised controlled trials (RCTs); however, all three reported on non-RCT evidence and the remaining six included
mostly one or two studies. We deemed all of the included reviews of high methodological quality.
Drug therapy for pain
There is no RCT evidence in a Cochrane Systematic Review exploring the efficacy of drug therapy for pain in MND.
Treatment for cramps
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There is evidence (13 RCTs, N = 4012) that for the treatment of cramps in MND, compared to placebo:
- memantine and tetrahydrocannabinol (THC) are probably ineffective (moderate-quality evidence);
- vitamin E may have little or no effect (low-quality evidence); and
- the effects of L-threonine, gabapentin, xaliproden, riluzole, and baclofen are uncertain as the evidence is either very low quality or the
trial specified the outcome but did not report numerical data.
The review reported adverse effects of riluzole, but it is not clear whether other interventions had adverse effects.
Treatment for spasticity
It is uncertain whether an endurance-based exercise programme improved spasticity or quality of life, measured at three months after
the programme, as the quality of evidence is very low (1 RCT, comparison “usual activities”, N = 25). The review did not evaluate
other approaches, such as use of baclofen as no RCTs were available.
Mechanical ventilation for supporting respiratory function
Non-invasive ventilation (NIV) probably improves median survival and quality of life in people with respiratory insufficiency and
normal to moderately impaired bulbar function compared to standard care, and improves quality of life but not survival for people with
poor bulbar function (1 RCT, N = 41, moderate-quality evidence; a second RCT did not provide data). The review did not evaluate
other approaches such as tracheostomy-assisted (’invasive’) ventilation, or assess timing of NIV initiation.
Treatment for sialorrhoea
A single session of botulinum toxin type B injections to parotid and submandibular glands probably improves sialorrhoea and quality
of life at up to 4 weeks compared to placebo injections, but not at 8 or 12 weeks after the injections (moderate-quality evidence from
1 placebo-controlled RCT, N = 20). The review authors found no trials of other approaches.
Enteral tube feeding for supporting nutrition
There is no RCT evidence in a Cochrane Systematic Review to support benefit or harms of enteral tube feeding in supporting nutrition
in MND.
Repetitive transcranial magnetic stimulation
It is uncertain whether repetitive transcranial magnetic stimulation (rTMS) improves disability or limitation in activity in MND in
comparison with sham rTMS (3 RCTs, very low quality evidence, N = 50).
Therapeutic exercise
There is evidence that exercise may improve disability in MND at three months after the exercise programme, but not quality of life,
in comparison with “usual activities” or “usual care” including stretching (2 RCTs, low-quality evidence, N = 43).
Multidisciplinary care
There is no RCT evidence in a Cochrane Systematic Review to demonstrate any benefit or harm for multidisciplinary care in MND.
None of the reviews, other than the review of treatment for cramps, reported that adverse events occurred. However, the trials were too
small for reliable adverse event reporting.
Authors’ conclusions
This overview has highlighted the lack of robust evidence in Cochrane Systematic Reviews on interventions to manage symptoms
resulting from MND. It is important to recognise that clinical trials may fail to demonstrate efficacy of an intervention for reasons
other than a true lack of efficacy, for example because of insufficient statistical power, the wrong choice of dose, insensitive outcome
measures or inappropriate participant eligibility. The trials were mostly too small to reliably assess adverse effects of the treatments. The
nature of MND makes it difficult to research clinically accepted or recommended practice, regardless of the level of evidence supporting
the practice. It would not be ethical, for example, to design a placebo-controlled trial for treatment of pain in MND or to withhold
multidisciplinary care where such care is available. It is therefore highly unlikely that there will ever be classically designed placebo-
controlled RCTs in these areas.
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We need more research with appropriate study designs, robust methodology, and of sufficient duration to address the changing needs-
of people with MND and their caregivers-associated with MND disease progression and mortality. There is a significant gap in studies
assessing the effectiveness of interventions for symptoms relating to MND, such as pseudobulbar emotional lability and cognitive and
behavioural difficulties. Future studies should use appropriate outcome measures that are reliable, have internal and external validity,
and are sensitive to change in what is being measured (such as quality of life).
P L A I N L A N G U A G E S U M M A R Y
Managing symptoms in motor neuron disease
Review question
What are the effects of treatments for managing symptoms in motor neuron disease (MND)?
Background
Motor neuron disease (MND), which is also known as amyotrophic lateral sclerosis (ALS), is an uncommon, incurable disease that
affects the nerves involved in movement. MND gets worse over time and affects muscles of the limbs, speech, swallowing and breathing.
People with MND experience a wide range of symptoms, including a number of physical ability limitations, pain, spasticity, cramps,
swallowing problems and difficulty breathing. It is important to recognise that clinical trials may fail to show that a treatment is effective
for several reasons that are not related to the effects of the treatment itself, for example when there are too few people in a trial, or
investigators choose an ineffective dose of a drug.
Review characteristics
We searched for Cochrane Systematic Reviews of treatments aiming to manage symptoms of MND. We found nine reviews that
fitted the objectives of this study. These reviewed randomized controlled trials (RCTs) of treatments for pain, cramps, spasticity, and
sialorrhoea, and assessed the effects of mechanical ventilation (non-invasive ventilation), enteral tube feeding, repetitive transcranial
magnetic stimulation (rTMS), therapeutic exercise, and multidisciplinary care. The trials compared the treatment with an inactive
treatment (placebo drug or sham therapy) or usual care.
Key results and quality of the evidence
There are currently many treatments in clinical use for pain, but no robust information currently exists on their effectiveness in people
with MND.
There is evidence that memantine and tetrahydrocannabinol are probably ineffective for cramps in ALS and that vitamin E may be
ineffective. There is too little information from RCTs on the effects of other treatments studied, including L-threonine, gabapentin,
xaliproden, riluzole, and baclofen. The review did not report adverse events other than for riluzole.
It is uncertain whether exercise improves muscle stiffness (spasticity). Exercise may improve disability; it may not improve quality of
life. Other interventions for spasticity have not been studied in RCTs.
Non-invasive mechanical ventilation probably improves survival and quality of life in ALS; it may not improve survival in people with
poor bulbar function. The review did not assess when to start NIV.
A single session of botulinum toxin injections into the salivary glands probably improves excessive saliva production and dribbling, and
quality of life in the short term (over weeks but not months).
At present, there is no evidence available from controlled trials to indicate whether or not there is a benefit to tube feeding for supporting
nutrition, nor is there any evidence to indicate whether multidisciplinary care is helpful or harmful. It is uncertain whether rTMS
is of benefit for improving disability or activity limitation in MND. Lack of evidence on multidisciplinary care or other treatments,
however, should not be interpreted as ineffectiveness.
Only the cramps review reported that adverse events occurred. The trials were mostly too small to reliably assess adverse events or rule
out uncommon events.
More research is required to determine which treatments help to manage symptoms for those living with MND, using suitable types
of studies and outcome measures.
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This overview is up to date to November 2016.
B A C K G R O U N D
Description of the condition
Motor neuron disease (MND), which is also known as amy-
otrophic lateral sclerosis (ALS), is an uncommon, fatal neurode-
generative disorder of the motor system in adults. It has a reported
population incidence of between 1.5 and 2.5 per 100,000 per-
son-years worldwide, with the only established risk factors being
age and family history (Turner 2007), and possibly military de-
ployment (Beard 2016). Several known genetic changes, such as
the pathological hexanucleotide repeat expansion in C9ORF72
(DeJesus-Hernandez 2011; Renton 2011), have been causally asso-
ciated with familial and sporadic ALS. The disease occurs through-
out adult life, with the peak incidence between 50 and 75 years
of age, and is more common in men (in the ratio 3:2) (Turner
2007). Historically, ALS was identified as a clinical syndrome dis-
tinguishable from other motor neuron diseases such as primary
lateral sclerosis, primary muscular atrophy, and progressive bulbar
palsy, based upon the location of first symptom and the extent
to which anterior horn cells or corticomotor neurons are initially
involved. However, it is increasingly evident that ALS is clinically
and pathophysiologically diverse, with clear overlap with fron-
totemporal dementia where there is early loss of frontotemporal
system neurons (Turner 2013). Death (usually from respiratory
failure) follows on average two to four years after onset, but some
people with MND may survive for a decade or more (Forsgren
1983).
Whilst the aetiology of MND is unknown, current evidence sug-
gests that multiple interacting factors contribute to motor neuron
injury in MND. The working hypothesis is that MND, like many
other chronic diseases, is a complex genetic condition and the rel-
ative contribution of individual environmental and genetic factors
is likely to be small (Al-Chalabi 2013). The three key pathogenetic
hypotheses invoke genetic factors, oxidative stress and glutamater-
gic toxicity, which result in damage to critical target proteins, such
as neurofilaments, and organelles such as mitochondria (Brown
1995; Cookson 1999; Shaw 1997). In addition, there is increasing
evidence supporting the hypothesis that altered ribonucleic acid
(RNA) processing and aggregation of abnormal proteins play a
major role in the pathogenesis of MND (Kim 2013; Verma 2013).
The diagnosis of MND is clinical and includes the presence of
upper motor neuron and lower motor neuron signs, progression
of disease and the absence of an alternative explanation. There is
no single diagnostic test at present that can confirm or entirely
exclude the diagnosis of MND. Clinicians rely mainly on clinical
history and examination, supported by electrodiagnostic studies
(Eisen 2001), and negative findings in neuroimaging and labora-
tory studies.
The symptoms in MND are diverse and challenging for both the
person with MND and the clinician. They include weakness, spas-
ticity, limitations in mobility and activities of daily living, commu-
nication deficits, dysphagia, respiratory compromise, fatigue, sleep
disorders, pain and psychosocial distress. The International Clas-
sification of Functioning, Disability and Health (ICF) defines a
common language for describing the impact of disease at different
levels: impairment (body structure and function) and limitation
in activity and participation (WHO 2001). Within this frame-
work MND-related impairments (weakness and spasticity), can
limit ‘activity’ or function (mobility, self-care) and ‘participation’
(driving, employment, family and social reintegration). ‘Contex-
tual factors’ that may be environmental (extrinsic) or personal (in-
trinsic) interact with all the other constructs to shape the impact
of MND on people with the condition and their families.
The burden of disease and economic impact of MND upon people
who have the condition, their caregivers (often family members)
and on society is substantial (Klein 1996; MND Australia 2015).
It is estimated that the per person cost of MND in Australia in
2015 was AUD 1.1 million with a total cost of MND in the
country of AUD 2.37 billion, comprising AUD 430.9 million in
economic costs and AUD 1.94 billion in burden of disease costs
(MND Australia 2015). A study of Australian people with MND
in the community (N = 44) showed that despite most requiring
a significant amount of help (more than three times a day) (Ng
2011), a quarter of these people received assistance solely from
family. It is therefore not surprising that primary caregivers have
been estimated to spend a mean of 9.5 hours a day caring for
a person with MND, even where there is paid assistance (Chio
2006).
At present, there are few approved drugs for the treatment of
MND. Riluzole is the only approved drug treatment for MND
in the United States, Australia and in many European countries.
It is thought to prolong median survival by about two to three
months at one year (Miller 2012). Edaravone, an antioxidant free
radical scavenger that is believed to relieve the effects of oxidative
stress, is licensed in Japan and currently under consideration in the
United States (ALS 2016). In addition, non-invasive ventilation is
also thought to prolong survival (Bourke 2006). In the absence of
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a cure or indeed any medical intervention which might stop the
progression of MND, the focus is on symptomatic, rehabilitative,
and palliative therapy with an overall aim of optimising quality of
life (QoL).
There are nine reviews in the Cochrane Library that address the
effectiveness of a wide range of symptomatic treatment thera-
pies for people with MND (Ashworth 2012; Baldinger 2012;
Brettschneider 2013; Dal Bello-Haas 2013; Fang 2013; Katzberg
2011; Ng 2009; Radunovic 2013; Young 2011). This overview
draws together the findings from these reviews to make the infor-
mation more accessible.
Description of the interventions
This review provides an overview of symptomatic treatments for
people with MND. Therefore, reviews of therapies that can al-
ter symptoms but which do not target the processes underlying
MND are included. Therapies include those that target MND
at the impairment level, such as mechanical ventilation for respi-
ratory insufficiency, enteral feeding for maintenance of nutrition
impairment, and treatments for spasticity, sialorrhoea, cramps and
pain; and those that target MND at the level of activity and par-
ticipation, such as multidisciplinary care, repetitive transcranial
magnetic stimulation (rTMS) and therapeutic exercise.
How the intervention might work
A wide range of interventions is used to treat the diverse symptoms
and impairments in MND. At the level of impairment, interven-
tions include the following:
• Mechanical ventilation (tracheostomy and non-invasive
ventilation) might prolong survival and optimise QoL by
supporting ventilation in those with clinically significant
respiratory muscle weakness.
• Enteral feeding might improve weight maintenance,
survival, and QoL by providing a safe and reliable route for
nutrition in people with MND who may have a combination of
dysphagia, poor appetite, and impaired ability to feed themselves
leading to reduced oral intake and malnutrition/dehydration.
• Spasticity treatments vary widely and may include
physiotherapy (for example, therapeutic exercises, stretching,
positioning), modalities (for example heat, cold, vibration,
electrical stimulation), prescription medication (for example
baclofen), non-prescription medication (for example vitamins),
chemical neurolysis (botulinum toxin), surgical interventions
(for example intrathecal pumps) and alternative therapies (for
example reflexology). How the interventions might work varies
widely from one intervention to another. Most commonly,
stretching techniques are used in combination with one or more
’true’ muscle relaxants (such as baclofen) (Carter 1998), and such
interventions work by lengthening (with or without the
assistance of weakening) the agonist muscle.
• Sialorrhoea treatments include suction, drug treatments
and more invasive approaches, such as injection of botulinum
toxin or irradiating the salivary glands, which may improve
sialorrhoea and QoL. These interventions work by reducing the
amount of saliva either through its removal (for example, by
suction) or reduction of salivary output (for example, by
anticholinergic medications and botulinum toxin injections).
• Cramps - as the origin of cramps is poorly understood, so
too are the mechanisms of treatment. Two different
pathophysiological mechanisms have been proposed: abnormal
excitation of the terminal branches of motor axons (Bertolasi
1993), and hyperexcitability or bistability of motor neurons at a
spinal level (Baldissera 1994). The aetiology of cramps in MND
and the mechanism of action of treatments remains uncertain.
• Pharmacological pain management works by reducing pain.
However, analgesics work on different pathways. For example,
paracetamol and non-steroidal anti-inflammatory drugs inhibit
the production of pain by inhibiting the production of
prostaglandins, whilst opiates (such as morphine) imitate natural
neuromediators by binding their receptors (such as endorphin
receptors).
At the level of activity and participation, interventions include the
following:
• Multidisciplinary care might reduce disability and improve
QoL by applying “a problem-solving education process” (Wade
1992), delivered by medical and allied health disciplines (such as
physiotherapy, occupational therapy, and speech therapy) that
are focused on maximising activity and participation.
• Transcranial magnetic stimulation might stimulate nerve
cells in superficial areas of the brain by applying a high-energy
magnetic field at the skull surface which induces a perpendicular
electrical field in the vertical plane through the cortex. It might
provide a non-invasive approach to condition the excitability and
activity of neurons (Kobayashi 2003), and at low frequency
(equal to or less than 1 Hz), bring a reduction in glutamate-
induced excitotoxicity, which may improve motor function in
MND (Ziemann 2004). At higher frequency (faster than 1 Hz),
it is thought that the increased expression of neurotrophic factors
could be neuroprotective (Angelucci 2004).
• Exercise might reduce disability and fatigue and improve
QoL by improving cardiovascular deconditioning and disuse
weakness.
Why it is important to do this overview
Nine published Cochrane Systematic Reviews in the Cochrane
Library address the effectiveness of a wide range of symptomatic
treatment therapies for people with MND specifically. This
overview draws together the findings from multiple Cochrane in-
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tervention reviews to give clinicians, policy makers and informed
consumers a ’friendly front end’ for data from a wide range of re-
views. This has the benefit of both making the information more
accessible and highlighting areas that need further research.
O B J E C T I V E S
To summarise the evidence from Cochrane Systematic Reviews of
all symptomatic treatments for motor neuron disease (MND).
M E T H O D S
Criteria for considering reviews for inclusion
Types of reviews
As per Chapter 22 of the Cochrane Handbook for Systematic Re-
views of Interventions (Becker 2011), we considered all Cochrane
Systematic Reviews for all treatments for motor neuron disease
(MND). These systematic reviews have the following characteris-
tics:
• pre-defined objectives;
• pre-defined criteria for eligibility of evidence;
• an objective systematic search for evidence applying
predetermined inclusion and exclusion criteria; and
• explicit and systematic methods for synthesising evidence,
which attempt to reduce bias.
We did not consider non-Cochrane Systematic Reviews or non-
systematic reviews for inclusion. Where a systematic review in-
cluded both MND and non-MND populations we included the
systematic review if the review reported results for people with
MND separately.
Types of participants
We included all forms of MND, regardless of clinical pattern (for
example bulbar or limb onset). In participants with amyotrophic
lateral sclerosis (ALS), we used the El Escorial and revised El Es-
corial criteria (Brooks 1994; Brooks 2000).
Types of interventions
We included all non-disease modifying and symptomatic inter-
ventions for MND, whether pharmacological or physical. We did
not include treatments that target the underlying disease process
in MND. These are the subject of a parallel overview of reviews on
disease modifying therapies in MND, which is in development.
Types of outcomes
In the narrative part of our overview, we report the outcomes
reported in the individual Cochrane Systematic Reviews. Where
possible, we categorised outcomes according to the International
Classification of Functioning, Disability and Health (ICF) (WHO
2001) into those that focused on:
• impairment - for example, forced vital capacity (FVC);
• disability or limitation in activity - for example, the revised
Amyotrophic Lateral Sclerosis Functional Rating Scale
(ALSFRS-R) (the domains of ALSFRS include speech, salivation
and swallowing; turning in bed, walking, climbing stairs;
dressing and hygiene, handwriting, cutting food; and respiratory
insufficiency, dyspnoea, orthopnoea);
• restriction in participation, and environmental or personal
context, or both - for example, mood of the person with MND
and their caregiver, satisfaction with services, social integration.
Many of the scales above predate the introduction of the concepts
of the ICF domains. The outcome measures often cross bound-
aries between the concepts of impairment, disability and partici-
pation. For example, ALSFRS lists impairments such as dyspnoea
and orthopnoea, as well as disabilities such as walking or climb-
ing stairs. Other important outcomes, such as survival and QoL,
are not strictly covered by the ICF concepts (although there is
again cross-over of boundaries between ICF concepts and these
outcomes). Nevertheless, the ICF provides an important frame-
work, which allows the use of a common standardised language
worldwide, hence its application in this overview. Scales used must
have been validated as having good reproducibility, face validity
and correlation with other scales measuring the same attribute.
Outcomes were divided into short-term (up to 3 months),
medium-term (3 to 12 months) and long-term (at least 12 months)
time points, for both primary and secondary outcomes.
Primary outcomes
Primary outcomes focus on domains within QoL and health status
after 12 months, such as the Short Form-36 (SF-36) or Visual
Analogue Scale (VAS) on life satisfaction and well-being. As QoL
is a broad concept, it could be measured by a broad range of scales
measuring various aspects of QoL.
Secondary outcomes
These include the following short-term, medium-term and long-
term outcomes:
• outcomes that relate to impairment - for example, forced
vital capacity (FVC);
• outcomes that relate to disability or limitation in activity -
for example, Amyotrophic Lateral Sclerosis Severity Scale
(ALSSS) and ALSFRS;
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• outcomes that relate to restriction in participation, and
environmental or personal context, or both - for example,
Caregiver Strain Index (CSI), Utrecht Coping List (UCL);
• survival;
• hospitalisation such as readmissions and hospital length of
stay (LOS); and
• cost-effectiveness of care.
We reported adverse events that may have resulted from the in-
tervention, as defined as events that were fatal, life-threatening, or
required hospitalisation. We also reported side effects from drugs.
This review assesses treatments for a range of symptoms. Not all
outcomes are relevant to all treatments in an overview of this sort.
We have reported outcomes where measured but not commented
where outcomes were not relevant to the intervention in question.
Search methods for identification of reviews
In November 2016, we searched the Cochrane Database of System-
atic Reviews (CDSR) for Cochrane Systematic Reviews of MND.
.
The search strategy is in Appendix 1.
Data collection and analysis
Selection of reviews
Two overview authors (LN and FK) selected systematic reviews
for inclusion and resolved disagreements by consensus following
discussion with a third overview author (MG).
Data extraction and management
Two overview authors (LN and FK) independently collected data
from published systematic reviews with a data collection form
designed to include all the data needed. We used ’Characteristics
of included reviews’ tables to present the essential features of the
included reviews.
We resolved disagreements by consensus following discussion with
a third author (MG).
We contacted the review authors or extracted data from the rele-
vant trials if further information was required.
We extracted the following characteristics from the reviews:





• outcomes in the review for which data are available; and
• limitations.
Assessment of methodological quality of included
reviews
Two overview authors, at least one of whom was not an author of
the original included reviews, independently assessed the method-
ological quality of each review included in the overview. For this
purpose we used the Assessment of Multiple Systematic Reviews
(AMSTAR) tool (Table 1) developed by Shea 2007, which has
acceptable inter-rater agreement, construct validity and feasibility
(Shea 2009). Two overview authors (LN and FK) also indepen-
dently assessed the quality of the evidence in the included reviews
with the GRADE approach (Guyatt 2008). In both cases, we re-
solved disagreements by discussion, if necessary with a third au-
thor (MG).
Data synthesis
We present data predominantly as a narrative review. We report the
evidence for each intervention from each review and its strength
in an ’Overview of reviews’ table using the GRADE approach. We
used the following criteria to assess the quality of the evidence:
study limitations (i.e. risk of bias), consistency of effect, impreci-
sion, indirectness, and publication bias. We assessed the evidence
using GRADE criteria where reviews lack ’Summary of findings’
tables. We present data by symptom.
In ’Overview of reviews tables’ we present:
• beneficial and harmful outcomes;
• frequency or severity of these outcomes in the control
groups;
• estimates of the relative and absolute effects of the
interventions;
• indications of the risk of bias (which may vary by outcome
and comparison); and
• comments.
Where we found more than one eligible review of a particular
intervention and the conclusions agreed, we report this; where the
conclusions differed, we further explored this, taking into account
the AMSTAR scores of the included reviews.
Due to the heterogeneity of the included systematic reviews, it
was not possible to perform statistically valid direct or indirect
comparisons on the interventions contained within this overview.
R E S U L T S
Description of included reviews
We identified 82 Cochrane Systematic Reviews in the Cochrane
Database of Systematic Reviews (CDSR). Of these, 30 passed the
first screening review and were selected for closer scrutiny. We ex-
cluded 18 reviews (Table 2); three others were reviews in palliative
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care conditions but did not have content relating specifically to
motor neuron disease (MND); hence we included nine reviews
(Table 3).
The nine included reviews address the effectiveness of a range
of symptomatic treatment therapies for people with MND at
both the level of impairment and at the level of activity and
participation. At the level of impairment, interventions in-
cluded: drug therapy for pain (Brettschneider 2013), treatment
for cramps (Baldinger 2012), treatment for spasticity (Ashworth
2012), mechanical ventilation for supporting respiratory function
(Radunovic 2013), treatment for sialorrhoea (Young 2011), and
enteral tube supporting nutrition (Katzberg 2011). At the level
of activity and participation, interventions included rTMS (Fang
2013), therapeutic exercise (Dal Bello-Haas 2013), and multidis-
ciplinary care (Ng 2009).
Methodological quality of included reviews
See Table 4 for methodological quality of the reviews and Table 5
for methodological quality of studies within included systematic
reviews.
All the included reviews achieved an Assessment of Multiple Sys-
tematic Reviews (AMSTAR) rating of either 10 or 11 out of 11
(Shea 2007), and we deemed them of high methodological quality.
There were three ’empty’ reviews (Brettschneider 2013; Katzberg
2011; Ng 2009), defined as reviews with no included studies. For
these reviews, a number of criteria were not applicable (character-
istics of included studies provided; scientific quality of included
studies assessed and documented; scientific quality of included
studies used appropriately in formulating conclusions; appropri-
ate methods used to combine study findings; likelihood of publi-
cation bias; conflict of interest stated for both the systematic re-
view and included studies). None of the reviews that contained
included studies scored a point for “Conflict of interest stated for
both the systematic review and included studies”. Whilst all the
reviews clearly stated conflicts of interest for the review, none re-
ported conflict of interest for included studies within the review.
For all reviews with included studies, at least two review authors
independently assessed the risk of bias in each study using the
same tools. The review authors considered risk of bias for seven
methodological domains: random sequence generation, allocation
concealment, blinding of participants and personnel, blinding of
outcome assessors, incomplete outcome reporting, selective out-
come reporting and other sources of bias. We assessed these do-
mains according to the Cochrane Handbook for Systematic Reviews
of Interventions. We judged each of the criteria relating to the risk
of bias as ’low risk’, ’high risk’ or ’unclear risk’ and we resolved any
disagreements through discussion with a third author.
In Table 5 ’Overview of reviews’, we reported the evidence for each
intervention from each review and its strength using the GRADE
approach, using the criteria of study limitations (i.e. risk of bias),
consistency of effect, imprecision, indirectness, and publication
bias. In the reviews where the review authors had used GRADE
to determine the strength of the evidence for each intervention,
we reassessed the grading of evidence where we felt that a different
grade would more accurately reflect the level of evidence. For ex-
ample, in the review for treatment for cramps, the review authors
judged studies with very small sample sizes (underpowered to de-
tect an effect) but otherwise at low risk of bias to be of moder-
ate quality. We downgraded them to low quality in this overview.
Where the strength of evidence was based on a single study alone
with a low risk of bias, we decided that the quality of evidence
could at best be moderate and not high.
Effect of interventions
Interventions at the level of impairment
Drug therapy for pain
In the Cochrane Systematic Review by Brettschneider 2013, the
review authors found no randomised controlled trials (RCTs) or
quasi-RCTs on drug therapy for pain experienced as part of motor
neuron disease (MND). This was unsurprising given the ethical
concerns around designing a placebo-controlled trial for treatment
of pain in MND. The review authors therefore considered non-
randomised evidence in the form of retrospective case series of
more than five participants where people were treated consecu-
tively, and found 13 case studies suggesting that pain occurs in up
to 78% of people with MND and that frequency and intensity
of pain increases with ongoing disease. Pain was most frequently
associated with reduced joint mobility, cramps, or skin pressure
caused by immobility. Paracetamol or other non-steroidal anti-
inflammatory drugs (NSAIDs) were commonly used as first line
treatment. However, in the later stages of disease, opioids were
reported as more effective for pain and also had a concurrent ben-
eficial effect on dyspnoea and insomnia. The authors concluded
that pain was a common unresolved problem in MND. In the ab-
sence of any evidence from RCTs, and utilising non-randomised
evidence, they concluded that treatment for pain in MND should
follow the 1990 World Health Organization (WHO) Analgesic
Ladder (WHO 1990).
Treatment for cramps
Baldinger 2012 identified 13 RCTs (N = 4012), in which interven-
tions for cramps were studied in participants with MND, of which
one study (tetrahydrocannabinol) assessed cramps as the primary
endpoint. Twelve studies (of vitamin E, baclofen, riluzole, L-thre-
onine, xaliproden, gabapentin, or memantine) assessed cramps as a
secondary endpoint. The systematic review also included six stud-
ies (of creatine, gabapentin, indinavir, dextromethorphan, quini-
dine, or lithium) that assessed cramps as an adverse event, but
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we did not consider them in this treatment overview. Assessment
time points varied widely. The review did not report adverse events
from interventions for cramps other than for riluzole; it is unclear
whether other trials did not report adverse events or whether no
adverse events occurred (see Table 5). Most trials assessed cramps
at regular intervals (ranging from weekly to 12-weekly) and one
of the studies had a single assessment time point at 12 months.
In none of the studies was there a clear benefit from any of the
medications. However, many studies were underpowered to draw
a definite conclusion. Notably, the review authors identified no
studies using physical therapy as a therapeutic intervention for
cramps.
Treatment for spasticity
Ashworth 2012 found a single RCT addressing the treatment of
spasticity in MND, in which spasticity (as measured by the Ash-
worth Scale) was improved at 3 months following an endurance-
based exercise programme. The study had a very small sample size
(N = 25) and was at high risk of bias. Significantly, attrition was
high enough to be a “fatal flaw”: 30% of participants had been lost
at 3 months, 50% at 6 months, and so many at 9 or 12 months that
no further analyses could be done. There was no statistically signif-
icant improvement in QoL and no adverse events were reported.
The review authors concluded that based on this single study, it
was not possible to determine whether individualised moderate-
intensity endurance-type exercise was beneficial or harmful and
that current practice, which includes anti-spasticity drugs such as
baclofen and a programme of regular stretching, required more re-
search, especially considering the potential harm from these drugs
through worsening muscle weakness and function.
Mechanical ventilation for supporting respiratory function
Radunovic 2013 identified two RCTs involving 54 participants
with MND receiving non-invasive ventilation (NIV). The review
authors were unable to analyse one of the studies as it had incom-
plete data (6 out of 13 participants). It also had no clear proto-
col as it was originally designed as a pilot study and did not re-
ceive funding for continuation. Results of the Cochrane System-
atic Review were therefore based on a single well-conducted RCT
of non-invasive ventilation versus standard care, which was at low
risk of bias (N = 41). Outcomes included survival and QoL (mea-
sured until at least 12 months or until death). Overall median
survival was significantly improved in the NIV group (219 days
compared to 171 days for standard care) and the survival benefit
was predominantly in the subgroup with normal to moderately
impaired bulbar function. NIV also resulted in a benefit in the
maintenance of QoL for most of the duration of survival in this
subgroup. Whilst NIV did not prolong survival in participants
with poor bulbar function, there was a significant improvement
in the ’Mean Symptoms’ domain of the Sleep Apnoea Quality of
Life Index, but not in the Short Form-36 Health Survey Mental
Component Summary score. Function was not measured and no
adverse events were reported. The authors of the review reported
that, given the RCT confirmed previous observational studies,
which have shown survival advantage and improved QoL in peo-
ple with MND who start and can tolerate NIV at the onset of res-
piratory impairment, ethically it was unlikely that there would be
further randomised controlled trials of NIV in unselected cohorts
of people with MND. The review did not assess when to start
NIV. Additionally, the National Institute for Health and Clinical
Excellence has carried out a cost-effectiveness analysis using the
Markov Model and concluded that the use of NIV in the man-
agement of people with MND represents a cost-effective use of
resources (NICE 2010b).
Treatment for sialorrhoea
Young 2011 identified a single RCT relating to treatment of sialor-
rhoea in MND which involved botulinum toxin type B injections.
The results favoured a single session of botulinum toxin type B
injections to parotid and submandibular glands, which produced
both subjective and objective benefits in people with MND for
up to 4 weeks. However, effects appeared to be lost by 8 to 12
weeks. Other than the relatively small sample size (N = 20), the
study was methodologically robust (randomisation and analysis
appeared good and data completeness was satisfactory) and find-
ings were supported by other non-randomised trials (which were
included in the discussion); these were typically open label stud-
ies on the use of botulinum toxin to reduce saliva production in
MND. Although no adverse events were reported in this RCT,
serious adverse events such as infection of the salivary gland and
dysphagia have previously been reported with this intervention
(Winterholler 2001).
Enteral tube feeding for supporting nutrition
Katzberg 2011 did not identify any RCTs that evaluated the ef-
ficacy of percutaneous endoscopic gastrostomy (PEG) or other
feeding tube placement. There were, however, 11 non-RCTs re-
lating to PEG insertion that the review authors identified and dis-
cussed. All 11 studies tested for a possible survival advantage. Two
prospective and two retrospective studies reported a longer sur-
vival in people with MND (regardless of limb or bulbar onset) af-
ter PEG compared to people feeding orally, whilst one prospective
and six retrospective studies failed to find a survival advantage. The
trial authors noted, however, that the latter studies had multiple
design flaws, the major flaw being lack of control for confounders.
Katzberg and colleagues concluded that survival advantage was
weakly positive. Nutrition was not as rigorously studied, but the
three studies that did assess nutrition found a positive outcome
for PEG. The studies did not assess QoL effectively and the re-
view authors drew no conclusions about this outcome. In terms
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of safety, the frequency of minor complications of PEG tube in-
sertion ranged from 2% to 16% and major complications, mostly
comprising PEG failure, occurred in up to 45% of participants.
Complications during the procedure itself (including death) were
infrequently reported. There was little evidence to guide timing
of PEG insertion, with some evidence that PEG insertion may be
more risky in people with a forced vital capacity (FVC) less than
50%, but there is also evidence that even people with MND with
low FVC may still benefit from PEG placement, particularly when
NIV is used during the procedure. Four studies compared the
effectiveness and safety of percutaneous radiological gastrostomy
(PRG), which is also known as radiologically inserted gastrostomy
(RIG), to PEG and found them equally effective with similar rates
of complications.
Interventions at the level of activity and participation
Repetitive transcranial magnetic stimulation (rTMS)
Fang 2013 aimed to determine the efficacy of rTMS primarily on
disability or limitation in activity. Three studies with small sample
sizes (50 participants in total) compared rTMS with sham TMS.
There was heterogeneity in the rTMS technique with respect to
duration of treatment, frequency of rTMS and intensity of rTMS.
Outcome measurement time points also varied widely between
the three studies (4 weeks, 6 months, and 12 months). None of
the three studies provided detailed data on the ALS Functional
Rating Scale-Revised (ALSFRS-R) at six months which was the
pre-assigned primary outcome in the review. The trials provided
only statistical summary data, with no raw numerical data. Of the
two studies that provided statistical summary data on ALSFRS-
R at 6 months, the results were conflicting, with one indicating
a benefit and the other finding no statistical difference. Little or
no difference was seen between rTMS and sham TMS using ALS-
FRS-R and changes to muscle strength at 12 months. All three
studies had significant methodological limitations including lack
of information on random sequence generation or on allocation
concealment, incomplete outcome data, high attrition and lack of
intention-to-treat analyses. None of the trials reported any adverse
events associated with the use of rTMS. In view of the significant
methodological limitations, the review authors concluded that it
would be premature to make any judgement on the short-term or
long-term safety of rTMS.
Therapeutic exercise
Dal Bello-Haas 2013 identified two studies on the effects of ex-
ercise in people with MND, one of which (Drory 2001), primar-
ily investigated the effect of exercise on spasticity and is therefore
also reported in the review for treatment of spasticity (Ashworth
2012). The focus of the exercise differed: one described endurance
exercises; the other, resistive exercises. Both trials had small sample
sizes (in total 43 participants) and the risk of bias of Dal Bello-Haas
2007 was significantly lower than Drory 2001, which had high at-
trition (30% at 3 months, with subsequent attrition so significant
at 9 and 12 months that analyses could not be completed), no
allocation concealment and no blinding. Outcome measures used,
however, were similar in both studies and allowed pooling of data,
which showed statistically significant improvement in disability
(measured by ALSFRS) at 3 months, which was not sustained at
6 months. There were no statistical differences found in QoL,
fatigue, or muscle strength and, importantly, no adverse events
were reported. In people with MND, the lack of research evidence
means that some clinicians discourage strengthening or aerobic
exercise programmes. The safe range for therapeutic exercise is de-
pendent on the extent of disease involvement - a weak muscle is
more susceptible to overwork damage. This should be balanced,
however, with the effects of cardiovascular deconditioning and
disuse atrophy. The review authors concluded that the included
studies were too small to determine to what extent strengthen-
ing exercises for people with ALS are beneficial or harmful. They
therefore concluded that further studies are needed to determine
the ideal exercise prescription for people with MND, in terms of
both which exercise protocols are most beneficial or cause undue
risks and whether there is a subset of people with MND who re-
spond more positively to exercise.
Multidisciplinary care
In the systematic review by Ng 2009, the review authors found no
randomised or quasi-randomised controlled trials on multidisci-
plinary care for people with MND. Given the similar ethical con-
cerns around designing such trials for treatment of pain, this was
not unexpected. The authors considered observational, cohort and
cross-sectional studies with the understanding that contribution
of such studies to best evidence synthesis would be limited. The
review authors found five low- to very low-quality observational
studies that suggested very tentative evidence for QoL (mental
health domains) without increasing healthcare costs, reduced hos-
pitalisation (in outpatient settings), and improved disability (in
inpatient settings). None of the studies reported any adverse ef-
fects attributable to multidisciplinary care. The authors concluded
that whilst these findings were tentative, a gap in current research
should not be interpreted as proof that multidisciplinary care is
ineffective.
D I S C U S S I O N
Summary of main results
This overview draws together the findings from multiple Cochrane
Systematic Intervention Reviews to give clinicians, policy makers
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and informed consumers a ’friendly front end’ for data from a wide
range of reviews. It has highlighted the lack of robust evidence on
interventions to manage the symptoms resulting from MND. Very
few large controlled trials have been undertaken for this condition
in terms of symptom management. Three reviews were empty re-
views; however, all three reported on non-randomised controlled
trial (non-RCT) evidence and the remaining six included mostly
one or two studies. One review on treatment for cramps included
20 studies, but many of these studies were not primarily designed
to investigate treatment for cramps, the review did not fully report
adverse events of these interventions, and seven trials reviewed
cramps as adverse events. None of the reviews reported any adverse
effects or events as a result of treatment apart from medications
for cramps, which reported adverse events of riluzole (but did not
report on adverse events of other interventions). Given the lack
of robust evidence, it would be premature to judge the treatments
as ’safe’. It is important to recognise that clinical trials may fail to
show that a treatment is effective for several reasons other than that
the drug is ineffective, for example insufficient statistical power,
wrong choice of dose, insensitive outcome measures or inappro-
priate participant eligibility criteria. Therefore, a lack of evidence
does not necessarily equate to ineffectiveness and should not over-
ride clinical judgement and discussion between a clinician and the
person with MND.
By intervention/symptoms:
Comparisons were usual activities, usual care, or a placebo (inac-
tive) treatment.
Interventions at the level of impairment
Drug therapy for pain
There is no evidence for or against any drug therapy for pain for
MND.
Treatment for cramps
There is evidence from placebo-controlled trials that tetrahydro-
cannabinol (THC) and memantine are probably ineffective for the
treatment of cramps in MND (moderate-quality evidence) and
that vitamin E may have little or no effect (low-quality evidence).
The effects of L-threonine, gabapentin, xaliproden, riluzole, and
baclofen are uncertain, as the evidence is either very low quality or
the trial specified the outcome but did not report numerical data.
Treatment for spasticity
It is uncertain whether an endurance-based exercise programme
improves spasticity or quality of life (QoL) at 3 months compared
with usual activities. The review did not evaluate other approaches,
such as the use of baclofen.
Mechanical ventilation for supporting respiratory function
Non-invasive ventilation (NIV) probably improves median sur-
vival and quality of life in people with respiratory insufficiency
and normal to moderately impaired bulbar function, compared to
standard care, and improves QoL but not survival for people with
poor bulbar function.
Treatment for sialorrhoea
A single session of botulinum toxin type B injections to parotid and
submandibular glands probably improves sialorrhoea and QoL at
up to 4 weeks compared to placebo injections, but not at 8 or 12
weeks. The review did not evaluate other approaches as no trials
were available.
Enteral tube feeding for supporting nutrition
There is no RCT evidence for or against enteral tube feeding for
supporting nutrition in MND.
Interventions at the level of activity and participation
Repetitive transcranial magnetic stimulation (rTMS)
It is very uncertain whether or not rTMS improves disability or
limitation in activity in MND compared to sham rTMS.
Therapeutic exercise
Exercise may improve disability in MND at 3 months but not
QoL compared to usual activities or usual care.
Multidisciplinary care
There is no RCT evidence for or against multidisciplinary care in
MND.
By outcomes:
Primary outcome - quality of life
The following interventions probably improve QoL in MND:
• NIV for survival;
• botulinum toxin type B injections for treatment of
sialorrhoea 4 weeks after treatment.
The following intervention probably does not improve QoL:
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• botulinum toxin type B injections for treatment of
sialorrhoea (moderate-quality evidence) at 8 or 12 weeks.
The following intervention may lead to little or no difference in
QoL:
• endurance-based exercise programme for spasticity
treatment or resistive exercise programme (low-quality evidence)
at 3 months.
It is not known if the following interventions improve QoL:
• drug therapy for pain;
• drug therapy for cramps: THC, memantine, riluzole,
vitamin E, L- threonine, gabapentin, xaliproden, riluzole, and
baclofen;




Impairment - refer to individual interventions at the level of im-
pairment above.
Activity and participation as measured by ALSFRS
The following interventions may improve level of activity/reduce
disability (low-quality evidence):
• resistive exercise programme at 3 months.
It is uncertain whether or not the following interventions improve
level of activity or reduce disability because the quality of evidence
is very low:
• endurance-based exercise programme for treatment of
spasticity at 3 months;
• rTMS.
It is not known if the following interventions improve level of
activity/reduce disability:
• NIV;
• botulinum toxin type B injections for treatment of
sialorrhoea;
• drug therapy for pain;
• drug therapy for cramps: THC, memantine, riluzole,
vitamin E, L-threonine, gabapentin, xaliproden, riluzole, and
baclofen;
• enteral tube feeding for nutrition;
• multidisciplinary care.
Overall completeness and applicability of
evidence
This overview sought to determine the efficacy of interventions
used for the relief of symptoms at the level of impairment, activ-
ity and participation in people with MND. Only Cochrane Sys-
tematic Reviews with participants who had MND were included
in this overview. Due to the heterogeneity of the interventions,
we were unable to perform any mathematical or statistical direct
or indirect comparisons across reviews. Two reviews (treatment
of spasticity and therapeutic exercise) had an overlap of included
studies and there were many other symptoms in MND (such as
cognitive and behavioural impairment and pseudobulbar emo-
tional lability), which were not covered at all in this overview.
Protocols for Cochrane Systematic Reviews of diaphragm pacing
in ALS (Maguire 2014) and treatment of fatigue (Young 2014)
have been published and reviews are in development, There was
a relative lack of QoL data. Most of the trials were too small for
reliable adverse event reporting.
Quality of the evidence
It is current policy for the Cochrane Library to update reviews
as new evidence likely to change conclusions emerges. All of the
included systematic reviews have been updated within 5 years of
publication where there has been such evidence. Conclusions of
the reviews are therefore mostly reflective of current research find-
ings. All the systematic reviews were of robust methodological
quality although three were empty, hence many of the method-
ological quality criteria were not applicable and a conclusion is
that there is no high-quality evidence for these areas. All included
Cochrane Systematic Reviews used a standard quality assessment
tool (Cochrane ’Risk of bias’ tool), hence there was a uniformity
in assessment of bias. Conflicts of interest were clear within the re-
views themselves but not routinely reported for the included stud-
ies within the included systematic reviews. It would helpful for
this information to be presented in the reviews to allow for deter-
mination of potential biases in outcomes and conclusions drawn.
Updated Cochrane methodology now mandates the reporting of
conflicts from primary studies where available.
Of the Cochrane Systematic Reviews with included studies, most
had small numbers of studies (usually one or two only) each with
small numbers of participants. There was imprecision of the data
for measures of effect in many of the trials. High attrition rates
were also common and intention-to-treat analysis was not always
applied. Blinding of participants was difficult with most of the
interventions; and outcome assessors were also often not blinded.
Where participants and outcome assessors were clearly blinded
(Young 2011), by 12 weeks 70% of investigators and 90% of par-
ticipants guessed treatment allocation correctly, suggesting that
despite excellent attempts to maintain blinding, the double-blind
was not preserved. Regardless, the methodological quality of al-
most all the studies could have been improved with blinding of
outcome assessors. Additionally, there was significant heterogene-
ity of intervention within each review and outcomes also varied
widely. None of the studies addressed cost-benefits, nor the role
of caregivers and their needs.
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Potential biases in the overview process
All overviews are limited by the risks of bias of the included
Cochrane Systematic Reviews and their included studies. We
limited systematic review inclusions and extraction of data to
Cochrane Systematic Reviews. It is possible that the Cochrane
Systematic Reviews may not have sought unpublished or ongo-
ing studies via trials’ registries as this was not standard practice
at the time of publication of many of these reviews. We did not
seek additional information from authors of the included studies.
The high Assessment of Multiple Systematic Reviews (AMSTAR)
scores for the Cochrane reviews were reassuring for the quality
of the reviews. However, the use of GRADE criteria introduced
an element of subjective judgement although this is now widely
accepted as a quality tool. It was made more challenging as the
overview primarily assessed the included reviews rather than the
original studies, and review authors may assess and report study
quality in different ways. Judgement can be open to interpretation.
We made the decision to downgrade studies twice based on small
sample sizes, inadequately powered to detect an effect, which was
harsher than the decision of the authors of the original reviews. We
also decided that a single, albeit high-quality, study at low risk of
bias was at best able to provide moderate-quality evidence where
further research still had a likelihood of changing the estimate of
effect.
LN, FK and CY are authors of included systematic reviews. Two
overview authors, at least one of whom was not an author of the
original included reviews, independently assessed the methodolog-
ical quality of each review included in the overview.
Agreements and disagreements with other
studies or reviews
To the best of our knowledge, there are no other systematic
overviews on interventions to manage symptoms in people with
MND. Evidence-based practice for MND should include a) in-
tegration of best available scientific evidence, b) clinical expertise,
judgement, and agreement, and c) the incorporation of the values
and beliefs of people with MND. There is currently a gap between
the available evidence, clinical practice, and agreement between
clinicians and incorporation of patient values in the treatment of
people with MND (Cicerone 2005).
Whilst RCTs remain the ’gold standard’ for determining the ef-
fectiveness of interventions, concerns have been raised about the
application of RCTs in complex interventions such as rehabilita-
tion or multidisciplinary care (Cicerone 2005). For such complex
interventions, an alternative to RCTs may be the use of an obser-
vational approach - the Practice Clinical Trial or Clinical Practice
Improvement (CPI) method that acquires prospective or retro-
spective data without disrupting the natural milieu of treatment
(Gassaway 2005). These types of studies, however, are not gener-
ally included within Cochrane reviews. Cochrane Systematic Re-
views that in the future include non-randomised evidence, graded
for quality, may add to the volume of evidence in this overview,
but may make quality judgements harder.
Even with the study of effects of simple interventions or discrete
outcomes where RCTs are best suited, there are a number of logis-
tical and ethical reasons that makes treatment in MND particu-
larly challenging to study. MND is a relatively rare condition, het-
erogenous in clinical presentation and manifestations, and results
in a rapidly disabling population with high mortality rates. People
with MND often prefer to participate in disease-modifying phar-
maceutical trials that might slow disease progression over other
trials (Dal Bello-Haas 2007). Attrition is particularly common,
especially in trials requiring longer follow-up, as participants may
have difficulty attending clinic for follow-up due to respiratory
and mobility issues, rapid disease deterioration resulting in me-
chanical ventilation or death, long distances to travel to the clinic
for follow-up, and fatigue (Drory 2001).
Because of the nature of MND, it is also difficult to research
clinically accepted or recommended practice, regardless of the level
of evidence supporting the practice. It would not be ethical, for
example, to design a placebo-controlled trial for treatment of pain
in MND or to withhold multidisciplinary care where such care is
available. It is, therefore, highly likely that there will never be RCTs
available in these areas. Similarly, where there is some evidence
of benefit from a single RCT, such as in NIV, it is unlikely that
further RCTs of NIV in unselected cohorts of people with MND
would occur. Even when there are no RCTs available but there
is non-RCT evidence showing weak survival advantage, such as
in the case of enteral tube feeding, it is probably unlikely that
RCTs will be conducted. Regardless of the evidence available, local
practices also vary considerably, for cultural, financial or other
reasons. Assisted ventilation for example can be provided with
invasive (tracheostomy ventilation) or non-invasive means. Whilst
tracheostomy ventilation in MND is not encouraged in Europe
and North America (Borasio 2001; Yamaguchi 2001), it is the
predominant form of ventilation offered to people in Japan, where
the cost is fully covered by the government and medical insurance
(Kawata 2008).
Another issue relating to clinical trials is the choice of outcome
measures. Due to the widespread use of ALSFRS-R, when out-
comes at the level of activity limitation are measured, trials com-
monly use ALSFRS-R, which allows for pooling of data. QoL is
an important outcome measure for people with MND. QoL is
a broad concept however, and it is not easily incorporated in a
single quantitative statistically valid outcome measurement. Fur-
thermore the measurement has no anchor and people with MND
often report a high QoL, persisting throughout their disease due
to shifting expectations and to reprioritisation factors contribut-
ing to QoL (Simmons 2015). Many outcome measures for health-
related QoL are generic (e.g. SF-36), not fully validated for MND
and limited by floor effects (Jenkinson 2002; Young 1995). Al-
though measures specific for MND, such as the ALSAQ-40, have
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since been developed for use, they have yet to be widely taken
up. Some are heavily weighted towards physical function (e.g. AL-
SAQ-40) and do not include an existential element (perception
of purpose, meaning of life, capacity for personal growth) rele-
vant for persons with MND (Bromberg 2008). Other measures in
this population include the direct-weight version of the Schedule
of the Evaluation of Individual Quality of Life (SEIQoL-DW)
(Hickey 1996), which can be used for both people with MND
and their caregivers, but this scale is time intensive (Mountain
2004), and does not allow comparison between people. The World
Health Organization (WHO) pioneered the development of QoL
measures with a more global view (WHOQOL and WHOQOL-
BREF) (WHOQOL 1998a; WHOQOL 1998b). More recently,
a modified version of the McGill questionnaire, which also has
more global elements, was validated as an ALS-specific QoL ques-
tionnaire (the ALSSQOL) (Simmons 2006), and a shortened ver-
sion (ALSSQOL-R) has been validated through multicentre study
(Felgoise 2007). In general, the overall self-perceived well-being of
a person with MND is determined by wide-ranging factors includ-
ing physical, psychological, existential, religious, and financial, etc.
and a global instrument such as WHOQOL-BREF, SEIQoL-DW,
or ALSSQOL-R may be used (Simmons 2015). When assessing
the impact of a very specific therapeutic intervention, however,
global QoL instruments will likely be insensitive and therefore
a more specific instrument that is based on health-related QoL
should be chosen (Simmons 2015). For example, NIV improves
sleep quality but as the person deteriorates in health, they may ex-
perience loss of relationships or financial difficulties which would
affect global QoL. Not surprisingly, therefore, it was found that
NIV improved Sleep Apnoea Quality of Life Index but not SF-
36.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The limitations of the evidence base mean that absence of proof
for the following treatments cannot be interpreted as proof that
they are ineffective.
Drug therapy for pain
Pain is a common unresolved problem in motor neuron disease
(MND) and in the absence of any evidence from randomised
controlled trials (RCTs), treatment for pain in MND could follow
the 1990 World Health Organization Analgesic Ladder (WHO
1990).
Treatment for cramps
Cramps can cause pain and impair function. There is some ev-
idence of lack of efficacy for tetrahydrocannabinol, memantine
and vitamin E for cramps in MND. Other drug treatments may
work but have little or no evidence for or against their use. In the
absence of any studies relating to physical therapy, such therapies
might also be considered as a treatment option.
Treatment for spasticity
It is uncertain whether an endurance-based exercise programme
may be useful for the treatment of spasticity as the evidence is of
very low quality. In the absence of any RCTs relating to the current
practice of a programme of regular stretching, and use of drugs
such as baclofen, no statement can be made about efficacy based
on any high-quality study.
Mechanical ventilation for supporting respiratory function
Non-invasive ventilation probably has survival and QoL benefit in
people with good or moderate bulbar function, and QoL benefit
in people with poor bulbar function.
Treatment for sialorrhoea
Botulinum toxin type B injections to parotid and submandibular
glands are probably effective in the short term (up to 4 weeks).
There is probably no benefit for sialorrhoea beyond this time after
a single injection.
Enteral tube feeding for supporting nutrition
There is an absence of any evidence from RCTs for or against the
efficacy of percutaneous endoscopic gastrostomy (PEG) insertion
for supporting nutrition. Non-randomised and other study design
publications provide a rationale for this intervention.
Interventions at the level of activity and participation
Repetitive transcranial magnetic stimulation
It is uncertain whether rTMS improves disability.
Therapeutic exercise
Exercise may improve disability in the short term (3 months).
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Multidisciplinary care
There are no RCTs in this area. There is a clinical consensus that
multidisciplinary care should be provided where available and this
is reflected in the recently updated UK National Clinical Guide-
line Centre (NICE) recommendations (NICE 2016). The absence
of proof that multidisciplinary care is effective must not be inter-
preted as proof that this approach is ineffective.
Implications for research
This overview has highlighted a significant gap in the current
literature. There is need for:
1) appropriate study designs, robust methodology and longitudi-
nal data which address the changing needs-of people with MND
and their caregivers-associated with MND disease progression and
mortality;
2) studies to assess the:
• effectiveness of interventions on all symptoms relating to
MND, including symptoms such as pseudobulbar lability and
cognitive and behavioural difficulties;
• benefits of interventions on quality of life (QoL);
• effectiveness of specific interventions (and components),
such as:
◦ physical therapy for the treatment of cramps;
◦ drug treatments and stretching for spasticity;
◦ type, intensity, frequency of interventions; and
• the cost effectiveness of interventions;
• impact of interventions on people with MND and their
families;
• other factors that affect outcomes (support, adaptive aids
and equipment, end-of-life issues);
3) the use of appropriate outcome measures including:
• reliable and valid outcome measures which reflect domains
of the International Classification of Functioning, Disability and
Health (ICF), are sensitive to what is being measured (such as
QoL) and to end-of-life care needs;
4) research into different phases of MND, hence covering the
spectrum of care required for this population.
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A D D I T I O N A L T A B L E S
Table 1. AMSTAR tool: quality assessment criteria
Criteria Specific requirements
1. Was an ’a priori’ design provided? The research question and inclusion criteria should be established
before the conduct of the review
2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a
consensus procedure for disagreements should be in place
3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must
include years and databases used (e.g. CENTRAL, Embase, and
MEDLINE). Key words and/or MESH terms must be stated and
where feasible the search strategy should be provided. All searches
should be supplemented by consulting current contents, reviews,
textbooks, specialised registers, or experts in the particular field of
study, and by reviewing the references in the studies found
4. Was the status of publication (i.e. grey literature) used as an
inclusion criterion?
The authors should state that they searched for reports regardless
of their publication type. The authors should state whether or not
they excluded any reports (from the systematic review), based on
their publication status, language, etc
5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided.
6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original
studies should be provided on the participants, interventions and
outcomes. The ranges of characteristics in all the studies analysed
e.g. age, race, sex, relevant socioeconomic data, disease status,
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Table 1. AMSTAR tool: quality assessment criteria (Continued)
duration, severity, or other diseases should be reported
7. Was the scientific quality of the included studies assessed and
documented?
’A priori’ methods of assessment should be provided (e.g. for effec-
tiveness studies if the author(s) chose to include only randomised,
double-blind, placebo controlled studies, or allocation conceal-
ment as inclusion criteria); for other types of studies alternative
items will be relevant
8. Was the scientific quality of the included studies used appro-
priately in formulating conclusions?
The results of the methodological rigour and scientific quality
should be considered in the analysis and the conclusions of the
review, and explicitly stated in formulating recommendations
9. Were the methods used to combine the findings of studies
appropriate?
For the pooled results, a test should be done to ensure the studies
were combinable, to assess their homogeneity (i.e. Chi² for homo-
geneity, I²). If heterogeneity exists a random-effects model should
be used and/or the clinical appropriateness of combining should
be taken into consideration (i.e. is it sensible to combine?)
10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination
of graphical aids (e.g. funnel plot, other available tests) and/or
statistical tests (e.g. Egger regression test)
11. Was the conflict of interest stated? Potential sources of support should be clearly acknowledged in
both the systematic review and the included studies
Total Score
Each criterion judged as ’Yes’ (score one point), ’No’ (score no point), ’Can’t answer’ (score no point) or ’Not applicable’ (score one
point). Total score summed out of a maximum 11 points.
Table 2. Characteristics of excluded reviews
Study Reason for exclusion
Abdul Wahid 2015 Protocol only
Disease-modifying treatments (since published in CENTRAL, Issue 10, 2016 in the Cochrane Library)
Maguire 2014 Protocol only
Young 2014 Protocol only
Pastula 2012 Disease-modifying treatment
Beauverd 2012 Disease-modifying treatment
Yi 2012 Protocol only
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Table 2. Characteristics of excluded reviews (Continued)
Miller 2012 Disease-modifying treatment
Benatar 2009 Disease-modifying treatment
Bongioanni 2009 Protocol only
Not related to treatment
Sathasivam 2007 Protocol only
Disease-modifying treatment
Orrell 2007 Disease-modifying treatment
Diana 2006 Protocol only
Disease-modifying treatment
Bongioanni 2004 Disease-modifying treatment
Annane 2014 Results for people with MND are not reported separately
Payne 2012 Studies included in this review for people with MND are already covered in the included studies
Lee 2012 Not a systematic review
Good 2014 Studies included in this review for people with MND are already covered in the included studies
Paolo 2015 Not a systematic review
Table 3. Characteristics of included reviews
Author/year Date assessed as up
to date





July 2012 Any drug therapy,
given by any route,
in any dose, ad-
ministered to relieve
pain in ALS/MND
Not stated but as-
sumed one inter-
vention to another
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Table 3. Characteristics of included reviews (Continued)
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Table 3. Characteristics of included reviews (Continued)
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Katzberg 2011 September 2009 Placement of percu-
taneous endoscopic
gastrostomy (PEG)
or other tube feed-
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Table 3. Characteristics of included reviews (Continued)
fatigue as measured
by Fatigue Severity












July 2012 Progressive resis-
tance or strengthen-
ing exercise and en-
durance or aerobic
exercise





















• Change in rate
of decline of muscle
strength









(all at 3 months)
Ng 2011 July 2011 Multidisciplinary
care as defined by
any intervention de-
livered by two or
more allied health
Lower level or dif-
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*Not clearly covered by AMSTAR assessment
Abbreviations: ALSFRS: Amyotrophic Lateral Sclerosis Functional Rating Scale; FVC: forced vital capacity; QoL: quality of life; RCT:
randomised controlled trial; VAS: visual analogue scale
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NA N N N N NA N N NA
Total score
(n/11)
11 10 10 10 10 11 10 10 11
Y = Yes - criteria met (score one point), N= No - criteria not met (score 0 points), CA = Can’t answer (score 0 points), NA= not
applicable (score 1 point)
Table 5. Overview of reviews
Interventions at the level of impairment/symptoms
Drug therapy for pain
Author/year Participants Interventions Comparisons Outcomes in the
review for which
data are available






None Not applicable Not applicable Not applicable No RCTs found
Treatment for cramps
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Table 5. Overview of reviews (Continued)





























events) - not an
outcome of interest
in this review















Baclofen - 1 study
with high risk of
bias and very small
sample sizes; subjec-
tive impression of













given on number of
participants at 12
months or date of
last examination
Moderate:
THC - 1 study with
low risk of bias
Memantine - 1




Riluzole - 3 studies,
2 of which had high
risk of bias due to in-
complete reporting
and 1 at low risk of
bias; cramps listed as
an outcome but data
not reported
Xaliproden - 2 stud-
ies with low risk of
bias; cramps an out-
come but results not
given
Gabapentin
- 1 study with low
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tine and THC not
stated
risk of bias. Cramps
an outcome but data
not reported
Treatment for spasticity
Ashworth 2012 1 RCT N = 25 Endurance exercises “Usual activities” Primary outcome:
Reduc-
tion in spasticity in
favour of treatment
group (mean reduc-
tion of −0.43, 95%
CI −1.03 to 0.17 in
intervention vs in-
crease of 0.25, 95%
















1 trial with high




50% attrition by 6
months
Mechanical ventilation for supporting respiratory function
Radunovic 2013 1 RCT N = 41 Non-invasive venti-
lation (NIV)
“Standard care” Primary outcome:
Median survival was
48 days longer (219




12 to 91 days, P
= 0.0062). In sub-
group analyses, me-
dian survival of sub-
group with good or
moder-
Moderate:
1 trial with low risk
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Table 5. Overview of reviews (Continued)
ately impaired bul-
bar function was sig-
nificantly different
in favour of NIV





in NIV group vs 11
days in standard care
group). In partici-
pants with poor bul-
bar function, NIV
did not confer sur-




1) QoL - significant
benefit in favour of
NIV in maintenance
of QoL in good
or moderately im-
paired bulbar func-




mary score; P = 0.
0013 mean symp-




benefit in favour of




domain of the sleep
apnoea QoL index




not possible and it





a total of 54 par-
ticipants; however, 1
was a pilot study
with no study proto-
col and incomplete
data (data available
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Table 5. Overview of reviews (Continued)
2) Function - such as
ALSFRS - not mea-
sured
3) No adverse events
reported.
Treatment for sialorrhoea
Young 2011 1 RCT N = 20 Bo-









at week 2 and 4




38%, P < 0.05 at
week 2; treatment
90% improved,
placebo 44%, P < 0.
05 at week 4. No sta-
tistically significant




1) Volume of saliva
produced as mea-
sured with funnel
and tube over 5 min
- significant differ-
ence in favour of
treatment group at
week 2 (treatment 0.
07, SD 0.2; placebo
0.84, SD 0.8, P <
0.05) and week 4
(treatment 0.02, SD
0.04; placebo 0.97,
SD 0.5, P < 0.05),
but not at week 8 or
12
2) QoL as measured
by clinicians’ assess-




1 trial, small sample
size but low risk of
bias. By 12 weeks,
70% of investigators
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not placebo at week
2 but not at later
time points
3) No adverse events
reported
Enteral tube feeding for supporting nutrition
Katzberg 2011 None Not applicable Not applicable Not applicable No RCTs found
Interventions at the level of activity and participation
Repetitive transcranial magnetic stimulation
Fang 2013 3 RCTs, N = 50 Repetitive transcra-
nial magnetic stim-
ulation (rTMS)

















als of poor method-
ological quality (2 of





sizes and high attri-













in activity as mea-
sured by ALSFRS
in favour of exercise
groups (3 months)




Both trials had small
sample sizes.
1 trial had a low risk
of bias, whilst the
other had high attri-
tion (close to 30%
by 3 months), no
allocation conceal-
ment, and no blind-
ing
33Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.






in QoL (SF-36), fa-
tigue (fatigue sever-






Ng 2011 None Not applicable Not applicable Not applicable No RCTs found
Abbreviations: ALSFRS: Amyotrophic Lateral Sclerosis Functional Rating Scale; ALSFRS-R: Amyotrophic Lateral Sclerosis Functional
Rating Scale Revised; CI: confidence interval; MD: mean difference; QoL: quality of life; RCT: randomised controlled trial; SD:
standard deviation; SEIQOL-DW: Schedule for Evaluation of Individual Quality of Life-Direct Weighting; SF: Short Form Health
Survey; vs: versus.
1. The review includes 20 trials, of which 7 assess cramps as an adverse event. We did not report the trials of cramps assessed as an
adverse event in this overview.
A P P E N D I C E S
Appendix 1. Cochrane Database of Systematic Reviews search strategy
#1 MeSH descriptor: [Motor Neuron Disease] explode all trees
#2 “motor neuron disease” or “motor neurone disease” or “motoneuron disease” or “motoneurone disease”
#3 “Amyotrophic Lateral Sclerosis”
#4 Gehrig near (disease or syndrome)
#5 (#1 or #2 or #3 or #4)
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